Companies › Beijing Yongtai Ruike Biotechnology Company
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CAR-T-19 cell injection anti-CD19 chimeric antigen receptor T cell therapy | CD19 | Phase 2 | Relapsed B-cell Acute Lymphoblastic Leukemia | Apr 2027 |
| RC19D2 cell injection anti-CD19 chimeric antigen receptor (CAR-T) cell therapy | CD19 | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06047197 | RC19D2 cell injection | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma | Oncology | Dec 2026 |
| NCT06179524 | CAR-T-19 cell injection | Phase 2 | Relapsed B-cell Acute Lymphoblastic Leukemia | Oncology | Apr 2027 |
Shanghai Ming Ju Biotechnology Juventas Cell Therapy PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology Autolus
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.